The crosstalk between long non-coding RNAs and PI3K in cancer.

Long non-coding RNAs (lncRNAs) are able to positively or negatively regulate other genes expression in cis or in trans. Their effect can be achieved through RNA-protein, RNA-DNA, or RNA-RNA interactions. They can recruit transcription factors and act as scaffolds or guides for chromatin-modifying enzymes.

Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature.

Background: CUP represents a heterogeneous population of patients with systemic malignancy and variable outcomes. Identification of clinical, pathologic and laboratory parameters with prognostic utility could contribute to estimation of death hazard and tailoring of therapy.

Patients And Methods: Clinical, pathologic and laboratory data from 311 patients with CUP diagnosed in a single university centre from 1988 to 2011 were examined for prognostic significance in univariate, multivariate and Classification and Regression Tree (CART) analyses.

Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome.

A large amount of data indicates that non-coding RNAs represent more than the "dark matter" of the genome. Both microRNAs and long non-coding RNAs are involved in several fundamental biologic processes, and their deregulation may lead in oncogenesis. Interacting with the Polycomb-repressive complex 2 subunit EZH2, they could affect the expression of protein-coding genes and form feedback networks and autoregulatory loops.

DLK1-MEG3 imprinted domain microRNAs in cancer biology.

A rapidly growing body of evidence highlights the involvement of DLK1-MEG3 imprinted domain in cell biology and cancer pathogenesis. The imprinted domain contains protein-coding genes, long non-coding RNAs, and various small non-coding RNAs. The imprinted microRNAs located here interact with important transcription factors, modulate fundamental signaling cascades, form molecular signatures with diagnostic and prognostic potential, and could differentiate chemoresistant from chemosensitive disease.

High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment.

Gene copy number and protein expression of topoisomerase IIalpha were correlated to benefit from anthracyclines in various tumors. A retrospective series of 69 patients with DLBCL managed with CHOP chemotherapy were studied for immunohistochemical TopoIIalpha expression and numerical gene abnormalities by fluorescent in situ hybridization (FISH). The results were analyzed in relation to the expression of cell cycle proteins (Ki67, p53, HDM2, p21, p14, pRb, p16, and cyclins A, B1, D1, D2, D3, and E) and BCL6/CD10/MUM1/CD138 B-cell differentiation immunophenotype and outcome.